AbbVie, Inc.

ABBV

$104.2

+14.3% (1 year change)

Avg closing price

Price range

Market Cap

$178 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$10.4 Billion

Total revenue in the last quarter.

Net Income

$-756 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$4.74

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$4.72 (4.68%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

21.26x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$2.98 Billion

Earnings before interest expenses and taxes in the last quarter.

Employees

30,000

The number of full time employees.

Revenue & Earnings

Balance Sheet

AbbVie, Inc.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

News

The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback

The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24) AbbVie Inc (NYSE: ABBV ) Affimed NV (NASDAQ: AFMD ...

Benzinga Benzinga, 3 days ago
Cytokine Market To Observ Explosive Growth By 2020-2027 | Abbvie, Bayer, Novartis, Roche Holding, Sanofi, Biocon, Pfizer

Cytokine Market To Observ Explosive Growth By 2020-2027 | Abbvie, Bayer, Novartis, Roche Holding, Sanofi, Biocon, Pfizer

Cytokine Market Report covering detailed analysis, Competitive landscape, forecast, and strategies has been added to the Insight Partners. The study covers geographic analysis that includes regions...

OpenPR OpenPR, 16 days ago
Osteoarthritic Pain Management Treatment Market Analysis by Boehringer Ingelheim International GmbH, Abbott, AbbVie Inc., Astellas Pharma

Osteoarthritic Pain Management Treatment Market Analysis by Boehringer Ingelheim International GmbH, Abbott, AbbVie Inc., Astellas Pharma

Global Osteoarthritic Pain Management Treatment Market, By Type (Hip, Wrist, Spinal, Others), Diagnosis (Imaging), Treatment (Medication, Surgery, Therapy, Others), End-Users (Hospitals, Clinics, M...

OpenPR OpenPR, 16 days ago